Class-action complaint alleges misrepresentation, false advertising
Publication outlines implementation strategies in acute care
Approval decision expected in July
If approved, drug would be first single-dose oral therapy for BV
Implanted rods offer controlled release of buprenorphine
Monoclonal antibody targets nerve growth factor
Advisors voted 7–3 against approval, but patient advocates clamor for a cure
Xaracoll is on schedule for 2017 launch

P&T May 2016
Table of Contents


Editor’s Memo
Although the death rate from cancer has fallen in recent years, progress against these diseases is uneven. This issue focuses on research efforts to find treatments.
The Obama administration has announced a drive to cure cancer, although the mission has been under way for decades. How are researchers doing, and what is in store?


Medication Errors
We must ensure safer use of oral chemotherapy
Prescription: Washington
CMS stands pat on exchange formulary standards
Approvals, new indications, regulatory activities, and more
Coagulation factor IX (recombinant), albumin fusion protein (Idelvion) for hemophilia B; captisol-enabled melphalan hydrochloride (Evomela) for multiple myeloma; and antihemophilic factor (recombinant) (Kovaltry) for hemophilia A
Meeting Highlights
Key sessions at HemOnc Today covered systemic and locoregional use of immunotherapies. At the cardiology meeting, preventive strategies took center stage.